House Passes Framework for $3.5T Budget Bill That Will Include Key Drug Pricing Measures

The U.S. House this week passed a budget blueprint that will pave the way for a vote on a number of drug pricing measures. 340B providers hope to be spared from Medicaid pharmacy cuts.

The House of Representatives passed a $3.5 trillion budget framework bill on Tuesday that potentially clears the path for Democrats to make extensive changes to U.S. health care delivery, although the impact on the 340B program remains to be seen.

Read More »

As Biden and House Dems Prepare to Unveil Drug Pricing Plans, 340B Providers Fret Over About Lost Savings

HHS Secretary Xavier Becerra's plan to fight excessive drug prices will be published publicly in the coming weeks, a White House official said yesterday.

As President Biden and House Democrats prepare to unveil their drug pricing game plans, 340B stakeholders eagerly await word on key provisions that could either be helpful or result in significant lost revenue.  While the proposals are going to be

Read More »

Key House Democrats Keep Up Pressure on Insulin Manufacturers

U.S. House Energy & Commerce Committee Democratic leaders Frank Pallone (N.J.) and Diana DeGette (Colo.) have asked insulin manufacturers Lilly, Novo Nordisk, and Sanofi for information about their prices, revenues, and expenses.

U.S. House Energy & Commerce Committee Democratic leaders have sent letters to three major drug manufacturers demanding an explanation for the skyrocketing price of insulin. The E&C Committee has jurisdiction over the 340B program and plays an instrumental role on

Read More »

N.C. Lawmakers Debate Over the Reach of 340B “Pickpocketing” Protections

North Carolina lawmakers are debating whether to grant all 340B covered entities and their contract pharmacies, or only some, protection against discrimination by pharmacy benefit managers.

North Carolina lawmakers are debating whether to grant all 340B covered entities and their contract pharmacies, or only some, protection against discrimination by pharmacy benefit managers.

Last week Thursday, state House and Senate leaders appointed members to a conference committee

Read More »

PhRMA Challenges First State Law Protecting 340B Contract Pharmacy Program

In 2023, Arkansas became the first state to move to enforce a 340B contract pharmacy law as manufacturer restrictions continued to increase.

Arkansas has temporarily suspended enforcement of the nation’s first state law to address pharmaceutical manufacturer denials of 340B pricing on drugs when they are dispensed by contract pharmacies.

State Insurance Commissioner Alan McClain ordered the 90-day suspension on July

Read More »

Biden Lays Down Markers for Action to Lower Drug Prices

President Biden this morning called on Congress to let Medicare negotiate drug prices and make drug companies that raise their prices faster than inflation pay a penalty.

President Biden this morning called on Congress to let Medicare negotiate drug prices and penalize drug companies that raise their prices faster than inflation.

Biden said lawmakers should establish a firm cap on the amount that Medicare beneficiaries have to

Read More »

U.S. Senate Sets Stage for Action on Lowering Drug Prices

U.S. Senate Democrats, led by Chuck Schumer (N.Y.), are setting the stage for a vote soon on policy changes to lower drug prices.

The U.S. Senate on Tuesday voted 69-30 to pass a bipartisan infrastructure bill that includes two drug pricing provisions, neither directly 340B-related. The bill now moves to the U.S. House, which is on a seven-week summer break. The $1 trillion

Read More »

Wisconsin Lawmakers Introduce 340B Anti-Discrimination Measure but Leave Out Most 340B Hospitals

Wisconsin Gov. Tony Evers (D) is pushing for passage of legislation to eliminate payer and pharmacy benefit manager (PBM) discrimination against health centers, critical access hospitals, Ryan White HIV/AIDS program grantees, and their contract pharmacies.

Wisconsin Gov. Tony Evers (D) is pushing for passage of a package of 13 “Less for Rx” bills to control prescription drug costs, including one to eliminate payer and pharmacy benefit manager (PBM) discrimination against certain 340B covered entities.

The

Read More »

340B Report Publisher and CEO Says New Bipartisan 340B Bill is Win for Providers and Drug Industry

The PROTECT 340B solves "two of the most intractable challenges in the 340B program in one fell swoop," 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Omnicell.

U.S. Reps. David McKinley (R-W.Va.) and Abigail Spanberger’s (D-Va.) bipartisan PROTECT 340B Act (H.R. 4390) can “resolve two of the most intractable challenges in the 340B program in one fell swoop” while satisfying both covered entities and drug manufacturers, 340B

Read More »

Infrastructure Bill Excludes Spread-Pricing Language That 340B Entities Oppose

An infrastructure-spending bill nearing a vote in the U.S. Senate excludes Medicaid managed care “spread pricing” language that 340B entities have been fending off since 2019.

340B covered entities dodged a bullet Sunday when U.S. Senate negotiators released the text of a $550 billion bipartisan infrastructure-spending bill. It did not contain Medicaid managed care “spread pricing” language that entities have been fending off since 2019. Entities

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live